What is CBL-514 Peptide?
CBL-514 is a small-molecule injectable lipolysis agent—not a peptide—that induces targeted adipocyte apoptosis (programmed fat cell death) for localized subcutaneous fat reduction. 1, 2
Mechanism of Action
CBL-514 works by inducing apoptosis specifically in adipocytes (fat cells) at the injection site. When injected subcutaneously into areas of unwanted fat deposits, it triggers programmed cell death in adipocytes, leading to measurable reduction in fat volume and thickness without causing necrosis or nerve injury. 1, 2
The key distinction here is that CBL-514 causes apoptosis (controlled cell death) rather than necrosis (uncontrolled tissue death), which explains its favorable safety profile with no observed tissue necrosis or nerve damage in clinical trials. 1
Clinical Evidence and Efficacy
The most recent Phase 2b randomized controlled trial (2026) demonstrated robust efficacy for abdominal subcutaneous fat reduction 1:
- 76.7% of treated participants achieved ≥1-grade improvement on clinician-reported scales versus 18.9% with placebo (P<0.0001)
- MRI-confirmed fat volume reduction of 152.9 mL (20.3% reduction from baseline) compared to placebo (P<0.0001)
- Dosing: 2 mg/cm² (maximum 600 mg per treatment session), administered at 3-week intervals for up to 4 treatments
- Response timing: Most responders showed improvement after just 1-2 treatments
Earlier Phase 2 studies corroborate these findings, with the 2.0 mg/cm² dose achieving 24.96% abdominal fat volume reduction 2, and 69.6% of participants losing ≥150 mL subcutaneous fat 3.
Safety Profile
CBL-514 demonstrates a favorable safety profile across multiple trials 1, 2, 3:
- Most common adverse events: Mild, transient injection-site reactions
- No serious safety signals: No necrosis, nerve injury, or severe systemic toxicity observed
- Well-tolerated: Adverse events predominantly mild-to-moderate in severity
Clinical Context
While the FDA drug label reference 4 appears to list cosmetic ingredients unrelated to the injectable lipolysis agent, the research evidence clearly establishes CBL-514 as a minimally invasive pharmaceutical intervention for targeted fat reduction—representing a non-surgical alternative to liposuction or other invasive body contouring procedures.
Important caveat: CBL-514 is designed for localized cosmetic fat reduction, not for treatment of obesity as a chronic disease. It does not address the neurohormonal dysregulation underlying adiposity-based chronic disease (ABCD) 5, 6 and should not be confused with systemic obesity treatments.